This concept is supported by the clinical observation that biallelic loss of Beclin-1 has not been seen in cancer patients [49,65], and by in vitro experiments showing that autophagy deficiency achieved by small interfering RNA targeting Beclin-1 or Atg5 reduces cellular proliferation and increases the death of cancer cells [61,66,67]. Here, ATG5 is linked to cancer.